Intraperitoneal doxorubicin achieves access to mesenteric lymph nodes, case series of two patients.

Int J Surg Case Rep

Program in Peritoneal Surface Oncology, Washington Cancer Institute, Washington, DC, United States.

Published: December 2018

Background: Intraperitoneal chemotherapy has been used extensively to treat cancers that metastasize to the peritoneal surfaces. In the operating room the intraperitoneal chemotherapy is administered with moderate heat. The chemotherapy is used after surgery when there is minimal residual disease. Alternatively, intraperitoneal chemotherapy can be used long-term in an attempt to prevent the progression of disease in patients at high risk for peritoneal metastases to occur during follow-up.

Methods: Hyperthermic intraperitoneal chemotherapy (HIPEC) with doxorubicin was used to treat peritoneal metastases in two patients. These two patients required generous sampling of mesenteric lymph nodes because involvement of these lymph nodes was suspected on preoperative radiologic studies by computed tomography (CT). The lymph nodes, peritoneal fluid and plasma along with tumor tissue in one patient were subjected to a determination of doxorubicin chemotherapy concentrations by high pressure liquid chromatography (HPLC).

Results: The ratio of doxorubicin present in peritoneal fluid as compared to plasma was 80 in patient 1 and 50 in patient 2. There was an increased doxorubicin concentration within lymph nodes as compared to plasma. The accumulation of doxorubicin in lymph nodal tissue was 40 times that of plasma in patient 1 and 30 times that in patient 2. In patient 2, the concentration of doxorubicin in lymph nodes was very similar to the concentration of chemotherapy within tumor nodules.

Conclusion: Doxorubicin chemotherapy was not only present in peritoneal surface tissue but also a surprisingly high level was present in mesenteric lymph nodes in patients treated by HIPEC. This observation may have implications for interpreting clinical future studies performed with HIPEC. To our knowledge, this is the first time this pharmacologic information regarding intraperitoneal chemotherapy access to mesenteric lymph nodes has been reported.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312798PMC
http://dx.doi.org/10.1016/j.ijscr.2018.11.065DOI Listing

Publication Analysis

Top Keywords

lymph nodes
32
intraperitoneal chemotherapy
20
mesenteric lymph
16
lymph
9
chemotherapy
9
access mesenteric
8
nodes
8
peritoneal metastases
8
peritoneal fluid
8
doxorubicin chemotherapy
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!